Kalvista Pharmaceuticals Inc (KALV) - Net Assets
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) has net assets worth $17.00 Million USD as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($339.93 Million) and total liabilities ($322.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kalvista Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.00 Million |
| % of Total Assets | 5.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -62.91% |
| 10-Year Change | 343.76% |
| Growth Volatility | 98.34 |
Kalvista Pharmaceuticals Inc - Net Assets Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Kalvista Pharmaceuticals Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual net assets of Kalvista Pharmaceuticals Inc from 2013 to 2025. For live valuation and market cap data, see Kalvista Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | $95.39 Million | -53.82% |
| 2024-04-30 | $206.58 Million | +28.29% |
| 2023-04-30 | $161.03 Million | -13.00% |
| 2022-04-30 | $185.09 Million | -28.03% |
| 2021-04-30 | $257.19 Million | +207.09% |
| 2020-04-30 | $83.75 Million | -13.42% |
| 2019-04-30 | $96.74 Million | +254.96% |
| 2018-04-30 | $27.25 Million | -13.00% |
| 2017-04-30 | $31.33 Million | +45.73% |
| 2016-04-30 | $21.50 Million | -50.09% |
| 2016-03-31 | $43.07 Million | -12.65% |
| 2015-12-31 | $49.31 Million | +211.61% |
| 2015-04-30 | $-44.18 Million | -855.26% |
| 2014-12-31 | $-4.62 Million | +86.28% |
| 2014-04-30 | $-33.71 Million | -19.17% |
| 2013-04-30 | $-28.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kalvista Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 62443200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $50.00K | 0.05% |
| Other Comprehensive Income | $-5.21 Million | -5.47% |
| Other Components | $753.73 Million | 790.14% |
| Total Equity | $95.39 Million | 100.00% |
Kalvista Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Kalvista Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chengdu B-ray Media Co Ltd
SHG:600880
|
$820.74 Million |
|
Inly Media Co Ltd
SHG:603598
|
$820.83 Million |
|
Africa Oil Corp
TO:AOI
|
$820.85 Million |
|
Gubra A/S
CO:GUBRA
|
$820.85 Million |
|
Fujian MinDong Electric Power Co Ltd
SHE:000993
|
$820.24 Million |
|
Campus Activewear Limited
NSE:CAMPUS
|
$820.14 Million |
|
United Renewable Energy Co Ltd
TW:3576
|
$820.01 Million |
|
Navient Corp
NASDAQ:NAVI
|
$819.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kalvista Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 206,582,000 to 95,391,000, a change of -111,191,000 (-53.8%).
- Net loss of 183,444,000 reduced equity.
- New share issuances of 55,911,000 increased equity.
- Other comprehensive income decreased equity by 1,726,000.
- Other factors increased equity by 18,068,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-183.44 Million | -192.31% |
| Share Issuances | $55.91 Million | +58.61% |
| Other Comprehensive Income | $-1.73 Million | -1.81% |
| Other Changes | $18.07 Million | +18.94% |
| Total Change | $- | -53.82% |
Book Value vs Market Value Analysis
This analysis compares Kalvista Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-04-30 | $-39.02 | $26.65 | x |
| 2014-04-30 | $-46.51 | $26.65 | x |
| 2015-04-30 | $-37.75 | $26.65 | x |
| 2016-04-30 | $36.35 | $26.65 | x |
| 2017-04-30 | $3.23 | $26.65 | x |
| 2018-04-30 | $2.64 | $26.65 | x |
| 2019-04-30 | $6.41 | $26.65 | x |
| 2020-04-30 | $4.72 | $26.65 | x |
| 2021-04-30 | $13.47 | $26.65 | x |
| 2022-04-30 | $7.56 | $26.65 | x |
| 2023-04-30 | $5.77 | $26.65 | x |
| 2024-04-30 | $5.62 | $26.65 | x |
| 2025-04-30 | $1.92 | $26.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kalvista Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.63x
- Recent ROE (-192.31%) is below the historical average (-41.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -133.49% | 0.18x | 0.00x | $775.50K |
| 2014 | 0.00% | -1368.19% | 0.04x | 0.00x | $-2.31 Million |
| 2014 | 0.00% | -46065.52% | 0.00x | 0.00x | $-12.90 Million |
| 2015 | 0.00% | -400.55% | 0.27x | 0.00x | $-2.81 Million |
| 2015 | -50.39% | -85675.86% | 0.00x | 1.15x | $-29.78 Million |
| 2016 | -15.34% | -94385.71% | 0.00x | 1.15x | $-10.91 Million |
| 2016 | -53.20% | -536.15% | 0.09x | 1.15x | $-13.59 Million |
| 2017 | -59.38% | -1236.90% | 0.04x | 1.10x | $-21.74 Million |
| 2018 | -57.99% | -188.29% | 0.14x | 2.25x | $-18.53 Million |
| 2019 | -21.52% | -129.08% | 0.14x | 1.22x | $-30.49 Million |
| 2020 | -34.76% | -229.44% | 0.14x | 1.10x | $-37.49 Million |
| 2021 | -17.98% | -364.41% | 0.05x | 1.06x | $-71.96 Million |
| 2022 | -44.49% | 0.00% | 0.00x | 1.10x | $-100.85 Million |
| 2023 | -57.70% | 0.00% | 0.00x | 1.14x | $-109.01 Million |
| 2024 | -61.30% | 0.00% | 0.00x | 1.14x | $-147.30 Million |
| 2025 | -192.31% | 0.00% | 0.00x | 2.63x | $-192.98 Million |
Industry Comparison
This section compares Kalvista Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kalvista Pharmaceuticals Inc (KALV) | $17.00 Million | 0.00% | 19.00x | $820.37 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more